Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis

International Immunopharmacology

Volumn 9, Issue 7-8, 2009, Pages 824-830

  Mirandola, Sandra R ^a   Hallal, Dannie E M ^a   Farias, Alessandro S ^a   Oliveira, Elaine C ^a   Brandão, Carlos O ^a   Ruocco, Heloisa H ^a   Damasceno, Benito P ^a   Santos, Leonilda M B ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Autoimmunity; Cytokines; Myelin basic protein

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADOLESCENT; ADULT; BRAZIL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUTROPHILS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349254137     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.03.004     Document Type: Article

References (44)

1. Hafler D.A., Slavik J.M., Anderson D.E., O'Connor K.C., De Jager P., and Baecher-Allan C. Multiple sclerosis. Immunol Rev 204 (2005) 208-231 Review
2. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747 Review
3. Ota K., Matsui M., Milford E.L., Mackin G.A., Weiner H.L., and Hafler D. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346 (1990) 183-187
4. Hafler D.A., and Weiner H.L. MS: a CNS and systemic autoimmune disease. Immunol Today 10 (1989) 104-107
5. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., and Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179 (1994) 973-984
6. Buttmann M., and Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 7 (2007) 227-239 Review
7. De Jager P.L., and Hafler D.A. New therapeutic approaches for multiple sclerosis. Annu Rev Med 58 (2007) 417-432 Review
8. Filippini G., Munari L., Incorvaia B., Polman C., Dámico R., and Rice G.P. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361 (2003) 545-552
9. Calabresi P.A., Stone L.A., Bash C.N., Frank J.A., and McFarlan H.F. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients flowed by weekly MRI. Neurology 48 (1997) 1446-1448
10. Panitch H.S., Hirsch R.L., Schindler J., and Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37 (1987) 1097-1102
11. Dettk M., Scheidt P., Prange H., and Kirchmer H. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 17 (1997) 293-300
12. Hartung H.P., Reiners K., Archelos J.J., Michels M., Heidenreich F., Pflughaupt K.W., et al. Circulating adhesion molecules and tumor necrosis factor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 38 (1995) 186-193
13. Selmaj K.W. Tumor necrosis factor and anti-tumor necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann Rheum Dis 59 (2000) 94-102
14. Chofflon M., Jillard C., Gauthier G., and Grau G. Tumor necrosis factor production as possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 433 (1992) 523-531
15. Brandao C.O., Ruocco H.H., Farias Ados S., Oliveira C., Hallal-Longo D.E., Mirandola S.R., et al. Cytokines and intrathecal IgG synthesis in multiple sclerosis patients during clinical remission. Arq Neuro-psiquiatr 63 (2005) 914-919
16. Smith T., Hewson A.K., Kingsley C.I., Leonard J.P., and Cuzner M.L. Interleukin 12 induces relapse in experimental allergic encephalomyelitis in the Lewis rats. Am J Pathol 150 (1997) 1909-1917
17. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M.N., Cuzner M.L., et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 182 (1995) 1985-1996
18. Imitola J., Chitnis T., and Khoury S.J. Cytokines in Multiple sclerosis: from bench to bedside. Pharmacol Ther 106 (2005) 167-177
19. Segal B.M., Dwyer B.K., and Shevach E.M. An interleukin (IL-10/IL-12) immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 187 (1998) 537-546
20. Zhang X., Reddy J., Ochi H., Frenkel D., Kuchroo V.K., and Weiner H.L. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int Immunol 18 (2006) 495-503
21. Yasuda C.L., Al-Sabbagh A., Oliveira E.C., Diaz-Bardales B.M., Garcia A.A., and Santos L.M. Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion. Immunol Invest 28 (1999) 115-126
22. Khoury S.J., Hancock W.W., and Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with dowregulation of inflammatory cytokines and differential upregulation of Transforming Growth Factor b, Interleukin4, and Prostaglandin E expression in the brain. J Exp Med 176 (1992) 1344-1364
23. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
24. Deibler G.E., Martenson R.E., and Kies M.W. Large scale preparation of Myelin Basic Protein from central nervous tissue of several mammalian species. Prep Biochem. 2 (1972) 139-165
25. Santos L.M.B., Al-Sabbagh A., Londono A., and Weiner H.L. Oral tolerance to myelin basic protein induces regulatory TGFβ secreting T cells in Peyer's patches of SJL mice. Cell Immunol 157 (1994) 439-447
26. Hallal-Longo D.E., Mirandola S.R., Oliveira E.C., Farias A.S., Pereira F.G., Metze I.L., et al. Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta. J Interferon Cytokine Res 27 (2007) 865-873
27. Comabella M., Balashov K.E., Issazadeh S., Smith D., Weiner H.L., and Khoury S.J. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 102 (1998) 671-678
28. Balashov K.E., Smith D.R., Khoury S.J., Hafler D.A., and Weiner H.L. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4 T cells via CD40 ligand. Proc Natl Acad Sci USA 94 (1997) 599-603
29. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today 138 (1996) 138-146
30. Costa P.M., Yasuda C.L., Scagliusi S.M., Diaz-Bardales B.M., Maciel E., Damasceno B.P., et al. Pattern of Cytokines Secretion by peripheral blood cells of patients with Multiple Sclerosis in Brazil. Mult Scler 6 (2000) 293-299
31. Makhloufk K., Weiner H.L., and Khoury S.J. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J Neuroimmunol 119 (2001) 145-149
32. J. Losy and G. Michalowska-Wender, In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis. 2002; 106:44-46.
33. Jensen J., Draukauer M., and Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon beta1b. Cytokine 29 (2005) 24-30
34. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., and Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci. USA 92 (1995) 11,294-11,298
35. Ozenci V., Kouwenhoven M., Huang Y.M., Kivisakk P., and Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF alpha) and IL-10 secreting blood cells that is corrected by interferon-beta (IFN-beta). Clin Exp Immunol 120 (2000) 147-153
36. Sarchielli P., Critelli A., Greco L., Sokola E., Floridi A., and Gallai V. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A. Cytokine 14 (2001) 294-298
37. Rieckmann P., Albrecht M., Kitze B., Tumani H., Broocks A., Luer W., et al. Tumor necrosis factor a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37 (1994) 227-257
38. Sharief M.K., and Hentges R. Association between tumor necrosis factor α and disease progression in patients with multiple sclerosis. N Engl J Med 325 (1991) 467-472
39. Furlan R., Bergami A., Lang R., Brambilla E., Franciotta D., Martinelli V., et al. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J Neuroimmunol 111 (2000) 86-92
40. Petereit H.F., Nolden S., Schoppe S., Bamborschke S., Pukrop R., and Heiss W.D. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 8 (2002) 492-494
41. Correale J., Gilmore W., McMillian M., Mc Carthy K., Thy L., and Weiner L. Patterns of cytokine secretion by autoreactive proteolipid protein specific T cell clones during the course of multiple sclerosis. J Immunol 154 (1995) 2959-2968
42. Kennedy M.K., Torrence DS Pichia K.S., and Mohler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with Experimental Autoimmune Encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149 (1992) 2496-2505
43. Miller A., Al-Sabbagh A., Santos L.M.B., Prabhu Das M., and Weiner H.L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. J Immunol 151 (1993) 7307-7315
44. Hafler D.A., Kent S.C., Pietrusewicz M.J., Khoury S.J., Weiner H.L., and Fukaura H. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci 835 (1997) 120-131